Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Autolus Therapeutics (AUTL) over the last 7 years, with Q3 2025 value amounting to -$0.3.

  • Autolus Therapeutics' EPS (Basic) rose 322.58% to -$0.3 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.83, marking a year-over-year increase of 3196.72%. This contributed to the annual value of -$0.86 for FY2024, which is 2793.37% up from last year.
  • Per Autolus Therapeutics' latest filing, its EPS (Basic) stood at -$0.3 for Q3 2025, which was up 322.58% from -$0.18 recorded in Q2 2025.
  • Autolus Therapeutics' EPS (Basic)'s 5-year high stood at $0.53 during Q1 2021, with a 5-year trough of -$466.29 in Q3 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.26 (2023), whereas its average is -$24.9.
  • As far as peak fluctuations go, Autolus Therapeutics' EPS (Basic) skyrocketed by 10000.18% in 2021, and later plummeted by 19787.23% in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' EPS (Basic) stood at -$3.43 in 2021, then skyrocketed by 93.29% to -$0.23 in 2022, then plummeted by 95.65% to -$0.45 in 2023, then skyrocketed by 75.96% to -$0.11 in 2024, then plummeted by 177.29% to -$0.3 in 2025.
  • Its EPS (Basic) stands at -$0.3 for Q3 2025, versus -$0.18 for Q2 2025 and -$0.26 for Q1 2025.